Affordable Access

Publisher Website

A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.

  • O, Manigart
  • C, Trotter
  • H, Findlow
  • A, Assefa
  • W, Mihret
  • T, Moti Demisse
  • B, Yeshitela
  • I, Osei
  • A, Hodgson
  • Sl, Quaye
  • S, Sow
  • M, Coulibaly
  • K, Diallo
  • A, Traore
  • Jm, Collard
  • R, Moustapha Boukary
  • O, Djermakoye
  • Ae, Mahamane
  • Jf, Jusot
  • C, Sokhna
  • And 14 more
Published Article
DOI: 10.1371/journal.pone.0147928
UCSC Cancer biomedical-ucsc


The pattern of epidemic meningococcal disease in the African meningitis belt may be influenced by the background level of population immunity but this has been measured infrequently. A standardised enzyme-linked immunosorbent assay (ELISA) for measuring meningococcal serogroup A IgG antibodies was established at five centres within the meningitis belt. Antibody concentrations were then measured in 3930 individuals stratified by age and residence from six countries. Seroprevalence by age was used in a catalytic model to determine the force of infection. Meningococcal serogroup A IgG antibody concentrations were high in each country but showed heterogeneity across the meningitis belt. The geometric mean concentration (GMC) was highest in Ghana (9.09 μg/mL [95% CI 8.29, 9.97]) and lowest in Ethiopia (1.43 μg/mL [95% CI 1.31, 1.57]) on the margins of the belt. The force of infection was lowest in Ethiopia (λ = 0.028). Variables associated with a concentration above the putative protective level of 2 μg/mL were age, urban residence and a history of recent vaccination with a meningococcal vaccine. Prior to vaccination with the serogroup A meningococcal conjugate vaccine, meningococcal serogroup A IgG antibody concentrations were high across the African meningitis belt and yet the region remained susceptible to epidemics.

Report this publication


Seen <100 times